Tag: entrepreneurs
-
Venture Funds in U.S., Europe Raise More Cash in Q1
More venture capital (VC) funds in the U.S. successfully hit their fund-raising targets in the first quarter of 2012, and like their counterparts in Europe, raised more cash in the process, according to Dow Jones LP Source, a financial industry research service. Tracking VC fund-raising offers an early indicator of investment money for start-up companies…
-
New PhD Grad, Professor Form Building Technology Company
An engineering professor and recent PhD graduate at University of Toronto have developed a technology to protect tall buildings from high winds and earthquakes, and started a company to take the technology to market. Civil engineering professor Constantin Christopoulos and recent Ph.D. Michael Montgomery (pictured left) developed the technology over 10 years, and founded Kinetica…
-
Presage Biosciences, Millenium to Partner on Cancer Drugs
Presage Biosciences, a biotechnology company in Seattle, and Millenium, a division of Takeda Pharmaceuticals in Cambridge, Massachusetts, say the two companies will collaborate on the development of new cancer therapies. Financial terms of the agreement were not disclosed. Millenium develops cancer drugs, focusing on disease pathways or processes that feed cancer cells. The agreement will…
-
Programmed Nanoparticles Tested as Cancer Treatments
Researchers from four universities, three hospitals, and the biopharmaceutical company BIND Biosciences are testing a new form of cancer therapy using nanoscale particles designed to deliver a dose of targeted medicine to solid tumors. The findings, including results of early clinical trials, are published in this week’s issue of the journal Science Translational Medicine (paid…
-
University Licenses Research to Detect Airborne Toxins
University of California at Riverside is licensing an engineering professor’s research on detecting airborne toxins to a local company that plans to take the technology to market. Nano Engineered Applications Inc. plans to develop the research of chemical and environmental engineer Nosang Myung (pictured right) into handheld detection devices that can spot harmful substances in…
-
U.S. Angel Investment Deals, Dollars Jump in 2011
The number and dollar amounts of angel investment deals in the U.S. rose sharply in 2011, with financing for science-related companies comprising nearly half of those transactions. The summary report of angel investing released yesterday by the University of New Hampshire’s Center for Venture Research also shows more initial-stage involvement in start-up companies than in…
-
Challenge Seeks Risk Assessment Tool for Microloan Denials
A new challenge from InnoCentive calls for a tool to gauge the financial risk of people and organizations that were denied a microloan for their business. The challenge has a prize of $40,000 and a deadline of 30 May 2012. InnoCentive in Waltham, Massachusetts is a company the conducts open-innovation, crowd-sourcing competitions for corporate and…
-
Cisco Systems Unveils R&D Collaboration Plans in Russia
Cisco Systems in San Jose, California revealed plans for new collaborations in Russia’s Skolkovo project, the country’s scheme to develop a technology and innovation center outside Moscow. The strategy unveiled today is part of a larger initiative with Russia announced by Cisco in 2010. The Skolkovo project is Russia’s attempt to build a technology and…
-
Maryland University, VC Partner on Start-Up Accelerator
Loyola University in Baltimore, Maryland and Wasabi Ventures, a venture capital company in San Mateo, California, have begun a new-business accelerator near the university’s campus. As part of the collaboration, Wasabi’s co-founder Thomas “T.K.” Kuegler, a 1994 Loyola graduate, will serve as the university’s entrepreneur-in-residence. Loyola says the accelerator will provide opportunities for its students…
-
Private Equity Company Founds $50M Biologics Start-Up
Celtic Therapeutics, a private equity company in the U.S. and Europe, has started a new company to bring to market therapies based on antibody drug conjugates (ADCs) that bind to and kill cells with the targeted properties. The new company, known as ADC Therapeutics and based in Lausanne, Switzerland will have an initial investment of…